Table 2.
COVID-19 infection history and booster uptake of the studied population.
| Variable | Number | Frequency (%) | |
|---|---|---|---|
| COVID-19 infection | No | 55 | 28.1 |
| Yes | 141 | 71.9 | |
| Number of infections | One time | 113 | 80.1 |
| Two times | 23 | 16.3 | |
| Three times | 4 | 2.8 | |
| Onset | Before vaccination | 122 | 86.5 |
| After the first dose | 19 | 13.5 | |
| After the second dose | 35 | 24.8 | |
| After the third dose | 27 | 19.1 | |
| Vaccination timing | From a month to 3 months ago | 39 | 19.9 |
| From a week to one month ago | 12 | 6.1 | |
| Less than a week ago | 5 | 2.6 | |
| More than 3 months ago | 140 | 71.4 | |
| Vaccine first dose | AstraZeneeca (ChAdOx1, AZD1222) | 37 | 18.9 |
| Janssen (Ad26.CoV2.S) | 5 | 2.6 | |
| Sinopharm (BBIBP-CorV) | 20 | 10.2 | |
| Sinovac (CoronaVac) | 99 | 50.5 | |
| Sputnik V (Gam-COVID-Vac) | 35 | 17.9 | |
| Vaccine second dose | AstraZeneeca (ChAdOx1, AZD1222) | 36 | 18.4 |
| Janssen (Ad26.CoV2.S) | 5 | 2.6 | |
| Sinopharm (BBIBP-CorV) | 23 | 11.7 | |
| Sinovac (CoronaVac) | 96 | 49.0 | |
| Sputnik V (Gam-COVID-Vac) | 36 | 18.4 | |
| Vaccine booster | AstraZeneeca (ChAdOx1, AZD1222) | 28 | 14.3 |
| Janssen (Ad26.CoV2.S) | 71 | 36.2 | |
| Sinopharm (BBIBP-CorV) | 13 | 6.6 | |
| Sinovac (CoronaVac) | 81 | 41.3 | |
| Sputnik V (Gam-COVID-Vac) | 3 | 1.5 | |
| Primer doses type | Adenoviral-vector virus | 77 | 39.3 |
| Inactivated virus | 119 | 60.7 | |
| Booster dose type | Adenoviral-vector virus | 102 | 52.0 |
| Inactivated virus | 94 | 48.0 | |
| Time between primer and booster doses (months) | 1 month | 19 | 9.7 |
| 1 to 3 months | 33 | 16.8 | |
| 3 to 6 months | 92 | 46.9 | |
| More than 6 months | 51 | 26.0 | |
| State of mind during booster vaccination | Anxious | 12 | 6.1 |
| Worried | 18 | 9.2 | |
| Indifferent | 79 | 40.3 | |
| Serene | 85 | 43.4 | |